RxDoctor Payments DataLook up a doctor →

David Kessler, MD

Clinical Cardiac Electrophysiology · Austin, TXNPI 1447251178

Payments from drug & device makers

$118,678in general payments, 2019–2025

Across 1,639 payments — averaging $72.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$88K
  • Pfizer$12K
  • Johnson & Johnson$7K
  • Medtronic$5K
  • Biosense Webster, Inc.$3K
  • E.r. Squibb & Sons, L.L.C.$824
  • plus $3K from 24 others

What the payments were for

  • Speaking & faculty fees$27,51343%
  • Travel & lodging$8,18413%
  • Food & beverage$28,82145%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,678 in reported general payments places this provider in the 75th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$514,958
Medicare patients
1,379
Services billed
7,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,375$1,480,589
XareltoRivaroxaban667$795,390
MultaqDronedarone Hcl132$176,217
Dabigatran EtexilateDabigatran Etexilate Mesylate257$57,025
Flecainide Acetate883$27,235
Dofetilide43$14,699
EntrestoSacubitril/Valsartan16$10,749
PradaxaDabigatran Etexilate Mesylate39$10,429
Propafenone Hcl264$10,021
Metoprolol Succinate271$3,889
Amiodarone Hcl338$3,192
SotalolSotalol Hcl134$2,456
Potassium Chloride124$1,842
Furosemide201$1,030
Metoprolol Tartrate117$927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12,459$1,480,5891,375 claims
Johnson & JohnsonXarelto$6,562$795,390667 claims
Sanofi-aventis U.S. LLCMultaq$481$176,217132 claims
NovartisEntresto$123$10,74916 claims
Boehringer IngelheimPradaxa$35$10,42939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →